Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CNTN with free AI briefings, catalyst countdowns, and dilution alerts.

CNTN · Canton Strategic Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$37.2M Cash on Hand
22.6mo Cash Runway
Follow CNTN by email Get an email when CNTN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CNTN, unsubscribe in one click. Privacy

📣 What CNTN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

CNTN holds $37.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $4.9M/quarter from operations, an estimated runway of 22.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 53 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CNTN files for a raise →

👥 Who Owns CNTN

Insiders 1.2% Other 5%+ holders 17.7% Institutions (100 holders) 28.4% Public and other holders 52.7%
HolderTypeShares% of sharesAs of
Murtaza S. Akbar 5%+ holder (13G) 6,203,724 7.60% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 4,819,281 5.90% 2026-09-30
Broadridge Financial Solutions, Inc. 5%+ holder (13G) 4,187,548 5.13% 2026-01-30
LCV Fund VIII, L.P. 5%+ holder (13G) 4,044,927 4.95% 2026-01-30
Vincent S LoPriore
Executive Chairman, Director, 10% owner · +190,000 options
Insider 732,424 0.90% 2025-04-09
Gravitas Capital LP
10% owner · +190,000 options
Includes shares also reported by Vincent S LoPriore, counted once
Insider 732,424 0.90% 2025-06-20
Gary S. Stetz
Director · +82,500 options
Insider 134,175 0.16% 2026-05-22
Sireesh Appajosyula
CEO, Director · +547,886 options
Insider 64,868 0.08% 2025-06-20
Randy Milby
CEO, Director · +138,665 options
Insider 17,534 0.02% 2024-12-19
Kelly Anderson
Director · +52,353 options
Insider 6,300 0.01% 2025-06-23
Sanam Parikh
COO, Director · +105,000 options
Insider 1,770 0.00% 2025-06-20

Share count 81,638,745 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CNTN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CNTN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.